Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30984104 | 0.99 | ADORA2A (0.34) | ADORA2AADORA1 | |
| SCHEMBL30983799 | 0.73 | PDPK1 (0.33) | — | |
| SCHEMBL31626948 | 0.71 | — | — | |
| SCHEMBL8565 | 0.66 | ADORA2A (0.58) | ADORA2AADORA1 | |
| SCHEMBL31269071 | 0.65 | LIMK1 (0.33) | — | |
| SCHEMBL17289600 | 0.64 | ADORA2A (0.43) | ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL7290011 | 0.59 | HTR2C (0.49) | ADORA2A | |
| SCHEMBL8342338 | 0.59 | ADORA2A (0.49) | ADORA2AADORA1 | |
| SCHEMBL14347073 | 0.59 | PDPK1 (0.41) | — | |
| Pyrophosphoric Acid SCHEMBL6065977 | 0.58 | ADORA2A (0.44) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | ADORA2A 4548/4885ADORA1 4296/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | ADORA2A 4548/4885ADORA1 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.